MBX MBX Biosciences, Inc.
FY2025 10-K
MBX Biosciences, Inc. (MBX) filed its fiscal year 2025 10-K annual report with the SEC on Mar 12, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Clinical-stage biopharma developing novel precision peptide therapies for endocrine and metabolic disorders via proprietary PEP™ platform
- • New emphasis on once-weekly canvuparatide for chronic hypoparathyroidism with positive Phase 2 data; Phase 3 trial to start Q3 2026
Management Discussion & Analysis
- • Net loss $87.0M in 2025 vs $61.9M in 2024; operating expenses rose $29.9M to $98.1M
- • R&D expenses $79.2M (29.7% increase) driven by canvuparatide ($37.2M, up $15.6M) and MBX 4291 ($12.7M, up $1.9M); imapextide decreased $7.4M
Risk Factors
- • FDA regulatory risk: potential requirement for additional preclinical or clinical studies increasing costs and delaying approvals
- • Geopolitical/macroeconomic risk: $373.7M cash runway into 2029 threatened by economic uncertainty and geopolitical tensions impacting operations
Get deeper insights on MBX Biosciences, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.